Targegen, Inc.

Acucela Inc.

Medtronic Minimed, Inc.

Other

Glenn Noronha

John Hood

Chi Ching Mak

Richard Soll

Jianguo Cao

Joel Renick

Ved Prakash Pathak

Andrew McPherson

Binqi Zeng

Elena Dneprovskaia

Amitava Gupta

Ryo Kubota

Wolfgang J Wrasidlo

Karim Haroud

David J Vachon

Julien Sauvet

Christian Oggenfuss

Hans Bernhard

Beat Wyss

Ute Splittgerber

Xianchang Gong

Daniel L Lohse

Aaron M Heiss

Joseph C Walsh

Ningning Zhao

Colleen Gritzen

William P Van Antwerp

Jean-Noël Fehr

Bill C Ponder

John Doukas

Jonathan Reilly

Kathy Barrett

John Joseph Mastrototaro

Thomas Arnold Peyser

Joe H Satcher, Jr

Jean-Noel Fehr

Stephen M Lane

Ivor Royston

Brooks B Cochran

John D Hood

Andrew Mc Pherson

Daniel Lohse

A soft contact lens comprises a plurality of light sources coupled to a plurality of optical elements. The plurality of light sources and the plurality of optical elements are embedded in a soft contact lens material. Each of said plurality of optical elements generates an image focused in front of a peripheral retina of a wearer. In some embodiments, each of the images is focused at a distance in front of the peripheral retina at a location, and each of the images comprises a depth of focus and a spatial resolution. The depth of focus can be less than the distance, and the spatial resolution greater than a spatial resolution of the peripheral retina at the location.

Optical designs of electronic apparatus to decrease myopia progression

Optical designs of electronic contact lens to decrease myopia progression

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. 

Bi-aryl meta-pyrimidine inhibitors of kinases

The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases. 

Benzotriazine inhibitors of kinases

Use of bi-aryl meta-pyrimidine inhibitors of kinases

The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the JAK kinase family, and various other specific receptor and non-receptor kinases. 

Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases. 

2-amino&#x2014;5-substituted pyrimidine inhibitors

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.

Kinase inhibitors and methods of use thereof

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

Vasculostatic agents and methods of use thereof

Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. These biosensor molecules address the problem of obtaining fluorescence emission at wavelengths greater than about 500 nm. Biosensor molecules generally include an (1) an acridine-based fluorophore, (2) a linker moiety and (3) a boronate substrate recognition/binding moiety, which binds polyhydroxylate analytes, such as glucose. These biosensor molecules further include a 'switch' element that is drawn from the electronic interactions among these submolecular components. This fluorescent switch is generally 'off' in the absence of bound polyhydroxylate analyte and is generally &#x201c;on&#x201d; in the presence of bound polyhydroxylate analyte. Thus, the reversible binding of a polyhydroxylate analyte essentially turns the fluorescent switch &#x201c;on&#x201d; and &#x201c;off&#x201d;. This property of the biosensor molecules, as well as their ability to emit fluorescent light at greater than about 500 nm, renders these biosensor molecules particularly well-suited for detecting and measuring in-vivo glucose concentrations.

Analyte sensing via acridine-based boronate biosensors

Improved polymer matrices which incorporate fluorescent biosensor molecules as well as methods of making and using these polymer matrices are described. Such matrices can be used in fluorescent biosensors and biosensor systems, including those which are used in the detection of polyhydroxylated analytes such as glucose. The properties of the polymer matrices of the invention renders biosensors utilizing such matrices particularly well-suited for detecting and measuring in-vivo glucose concentrations.

Polymers functionalized with fluorescent boronate motifs and methods for making them

Growing community of inventors

Oceanside, CA, United States of America

Glenn Noronha